Fluasterone
Alternative Names: 16α-fluoro-DHEA; DHEA analogue 8354; HE 2500Latest Information Update: 02 Feb 2011
At a glance
- Originator Fels Institute for Cancer Research and Molecular Biology
- Developer Aeson Therapeutics
- Class Androstenols; Anorectics; Antihyperglycaemics; Antihyperlipidaemics; Antineoplastics; Hepatoprotectants; Phenanthrenes; Small molecules; Testosterone congeners
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Asthma; Cancer; Cardiovascular disorders
- Discontinued Actinic keratosis; Diabetes mellitus; Multiple sclerosis; Obesity; Psoriasis; Rheumatoid arthritis; Systemic lupus erythematosus
Most Recent Events
- 02 Feb 2011 No development reported - Phase-I for Cancer in Switzerland (Parenteral)
- 02 Feb 2011 No development reported - Phase-I for Cancer in United Kingdom (Parenteral)
- 02 Feb 2011 No development reported - Phase-II for Cardiovascular disorders in USA (PO)